Skip to main content
English
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
9 April 2018
Oryzon to present at upcoming international conferences
4 April 2018
ORYZON receives approval to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
5 March 2018
ORYZON Announces Publication of Paper in Cancer Cell establishing the relevance of ORY-1001 as an antileukemic differentiating drug
21 February 2018
Oryzon to present at upcoming international conferences
19 February 2018
ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2017
19 February 2018
Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry
5 February 2018
ORYZON Appoints Clinical Development Leader Lori A. Kunkel, M.D., as a Scientific Advisor
29 January 2018
ORYZON announces First Patient In in ORY-2001 MS Phase IIA trial SATEEN and presents new data on ORY-2001 at the third annual ACTRIMS Forum 2018 in San Diego
23 January 2018
ORYZON to present at two US investor conferences
4 January 2018
ORYZON to present at the Neuroscience Innovation Forum in San Francisco
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »